Shares of Burning Rock Biotech Limited (NASDAQ: BNR) plummeted 8.22% in intraday trading on Thursday after the company reported disappointing third-quarter 2025 financial results. The precision oncology company, which focuses on next-generation sequencing (NGS) technology, faced challenges in its core business segments despite overall revenue growth.

Burning Rock reported total revenues of RMB 131.6 million (US$18.5 million) for Q3 2025, representing a modest 2.3% increase from the same period last year. However, the company's central laboratory and in-hospital businesses experienced significant declines. Revenue from the in-hospital business decreased by 17.1% to RMB 52.8 million, while the central laboratory business saw a 7.9% drop to RMB 36.8 million. These declines were partially offset by a 68.6% increase in revenue from pharma research and development services, which reached RMB 42.0 million.

Despite the revenue growth, Burning Rock reported a net loss of RMB 16.8 million (US$2.4 million) for the quarter. While this marks an improvement from the RMB 35.7 million loss in the same period of 2024, it still indicates ongoing profitability challenges for the company. The persistent losses, combined with the revenue declines in key business segments, likely contributed to investor concerns and the subsequent stock price drop.

Burning Rock's management highlighted some positive developments, including improved gross margins and reduced operating expenses. However, these improvements were not enough to offset the market's reaction to the overall financial performance. As the company continues to navigate a challenging market environment and transitions towards in-hospital testing, investors will be closely watching for signs of stabilization and growth in its core business segments in the coming quarters.